<DOC>
	<DOC>NCT02309385</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.</brief_summary>
	<brief_title>Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis</brief_title>
	<detailed_description>This is a multicenter, randomized, parallel group, double-masked, active- controlled study. Subjects will be enrolled and randomized to either 8 % or 15% DSP-Visulex with placebo drops or Vehicle-Visulex (V-Visulex) with prednisolone acetate 1% eye drops. All subjects will receive concomitant treatment with cyclopentolate.</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Uveitis, Anterior</mesh_term>
	<mesh_term>Iridocyclitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Noninfectious anterior uveitis lntraocular pressure &gt; 25mm Hg OU. Previous occurrence of an acute episode of anterior uveitis in affected eye(s) within 4 weeks prior to Visit 1. Historical or active intermediate or posterior uveitis in affected eye(s). Clear systemic causes of uveitis that may require or have required systemic treatment Uveitis suspected to have resulted from recent surgery or trauma. Use of ocular medication of any kind in affected eye(s) more than 2 days prior to Visit 1, excluding artificial tears, topical allergy medications, eyelid scrubs. Current use, or anticipated initiation during the study, of a corticosteroid or an immunosuppressant agent by any route (oral, inhaled, ocular, dermal). Current stable use is allowed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>uveitis</keyword>
	<keyword>acute uveitis</keyword>
	<keyword>anterior uveitis</keyword>
	<keyword>dexamethasone sodium phosphate</keyword>
	<keyword>non-infectious uveitis</keyword>
	<keyword>DSP-Visulex</keyword>
	<keyword>Aciont</keyword>
</DOC>